Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

179.17 +0.11 (+0.06%)
Streaming Delayed Price Updated: 12:02 PM EDT, Jun 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 374,985
Open 178.50
Bid (Size) 179.16 (2)
Ask (Size) 179.35 (1)
Prev. Close 179.06
Today's Range 175.46 - 181.00
52wk Range 105.43 - 192.79
Shares Outstanding 181,934,500
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
This Analyst Believes Seagen Is Evaluating Strategic Alternatives
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2022
Upgrades 
Via Benzinga

Performance

YTD
+13.51%
+13.51%
1 Month
+32.05%
+32.05%
3 Month
+26.57%
+26.57%
6 Month
+12.74%
+12.74%
1 Year
+12.98%
+12.98%

More News

Read More
Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ
Via Benzinga
Where Seagen Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022
Via Benzinga
Seagen Surges As Merck Takeover Deal Reportedly Accelerating
Via Investor's Business Daily
Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24
Via Benzinga
Merck Shows Takeover Interest In Seagen: WSJ
Via Benzinga
SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know
Via Benzinga
89 Biggest Movers From Friday
Via Benzinga
SGEN Stock Alert: Is Merck About to Buy Seagen?
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
33 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Embattled Biotech Seagen Rockets On Rumors Merck Could Buy It
Via Investor's Business Daily
$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today
Via Benzinga
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications
Via Benzinga
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Seagen Inc.
Via Business Wire
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Genmab A/S
Via Business Wire
10 Biggest Price Target Changes For Monday
Via Benzinga
ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
5 Growth Stocks to Buy Now
Via InvestorPlace
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
From Takeda Pharmaceutical Company Limited
Via Business Wire
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
Via Benzinga
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Seagen CEO Clay Siegall Resigns After Domestic Violence Arrest
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.